alzheimer's treatment

The FDA fully approved Biogen Inc.’s (NASDAQ: BIIB) Alzheimer’s treatment Leqembi on Thursday, becoming the first Alzheimer’s antibody treatment to reach full approval. Alzheimer’s disease is a brain disease that leads to cognitive decline, impacting more than six...

The study focused on the potential of rare cannabinoids in the treatment of neurodegenerative diseases like Alzheimer's. According to the researchers behind the study, this breakthrough research opens new avenues for addressing the unmet medical needs of patients with conditions like Alzheimer...

Tesla Inc (NASDAQ: TSLA) CEO Elon Musk's startup Neuralink brain chip could help treat morbid obesity; that's what Musk believes. Echoing Musk's statement, scientists say it's not an impossibility.  Responding to a Twitter post on the same line, Musk said that it is...

Eisai Co Ltd (OTC: ESALY) and its U.S. partner Biogen Inc's (NASDAQ: BIIB) Alzheimer's treatment Aduhelm (aducanumab) will be used by more than 300 American medical institutions. The treatment is already being administered to some patients, the head of Eisai's...

Alzamend Neuro Inc (NASDAQ: ALZN) contracted Altasciences to conduct a six-month Phase 1 comparative bioavailability study for AL001 for dementia related to Alzheimer's disease in September 2021.  AL001 is a lithium-delivering ionic cocrystal under development as an oral...

Wall Street analysts suggest that Biogen Inc (NASDAQ: BIIB) stock is about to see a significant selloff and could witness volatility until the Food and Drugs Administration (FDA) review process comes to a close in March 2021, Bloomberg reports. The analyst forecasts were...

Alzheimer's drug research has a high failure rate, and symptoms of the disease start appearing long after amyloid plaques — which are responsible for interruption of cell-to-cell signal transfer — deposit on the brain. The Analyst Roth Capital Partners analyst Robert LeBoyer...

Some on the Street consider Biogen Inc (NASDAQ: BIIB)’s bull thesis to be largely played out. But one analyst sees room for 15-percent upside.  The Rating UBS analyst Carter Gould upgraded Biogen to Buy and raised their price target from $318 to $410. The Thesis Biogen’s...

Eli Lilly and Co (NYSE: LLY) fell steeply Wednesday after it announced that its Alzheimer's disease treatment candidate solanezumab didn't meet the primary endpoint in a late-stage clinical trial dubbed EXPEDITION3. In a sympathy move, Biogen Inc (NASDAQ: BIIB) also traded notably lower. Is the...

Wall Street analysts have shown a bullish sentiment towards pharmaceutical and healthcare companies that focus on the treatment of Alzheimer's disease. A few days ago, BMO Capital Market's hosted a conference call with Dr. Dennis Selkoe, a leading Alzheimer's diseases researcher....

Mixed news came out this week on research into Alzheimer's.   New studies suggest the rate of Alzheimer's and other forms of dementia is dropping in the United States and other developed countries. Meanwhile, Big Pharma's years-long battle to find a treatment, if not a cure,...